SlideShare a Scribd company logo
1 of 41
Download to read offline
Diagnosis of
Infected total knee arthroplasty
Warakorn Jingjit, MD
Orthopaedic Department, Faculty of Medicine
Chiang Mai University
One of the most devastating & challenging complication
Immense financial & psychological burden
Cost of treatment 15,000 - 60,000 $ / TKA
Hebert CK, CORR, 1996
Sculco TP, Orthopedics, 1995
Incidence
• 0.39% in primary TKA
• 0.97% in revision TKA
Projection of the TKA & THA number

Kurtz S, JBJS, 2008
Projection of the TKA & THA infection

Kurtz S, JBJS, 2007
Risk factors
1.
2.
3.
4.

Patient / host
Surgical environment
Surgical technique
Postoperative management
Risk factors
Patient / host
• Immunocompromise

•

– RA (4.4%)
– Steroid therapy
– DM (7%)
– Poor nutrition
• Albumin <3.5g/dl: 7-fold
• Lymphocyte <1,500 cells/mm3: 5-fold
•
– HIV
– Organ transplant
•

•
•
•

Hypokalemia
Tobacco use
Obesity

•
•
•

Debilitation
–
–
–
–
–

Advanced age
Alcoholism
Renal failure
Cirrhosis
Prolonged pre-op
hospitalization

Hypothyroidism
Previous surgery
Psoriasis
Previous infection
Concurrent infection
Risk factors
Surgical environment
• Personnel
• Clean air
Laminar air flow, UV light
• Surgical attire
• Operative site preparation
Ritter MA, CORR,1988
Ritter MA, Orthop Clin North Am,1989
Berg M, JBJS (Br), 1991
Ritter MA, CORR, 1999
Peersman G, CORR, 2001
Risk factors
Surgical technique

•

Surgical time

Operative time > 2.5 hrs
Peersman, CORR, 2001
Risk factors
Surgical technique
Prophylactic antibiotic
Single most effective method of ↓ infection
1st gen. cephalosporin
Allergy  vancomycin / clindamycin
30-60 min before incision
(peak serum bone conc. within 20 min)
 Repeat every 4 hrs & bleed >1,000 ml
 Discontinue 24 hrs after surgery




Risk factors
Surgical technique
Prophylactic antibiotic bone cement

•

High risk 1o TKA, revision TKA
Risk factors
Surgical technique
Implant

• Hinged prosthesis
• Infection rate at 10 yrs ~ 15%

• Bengtson S, Acta Orthop Scand, 1991
• Hanssen AD, CORR, 1995
• Schoifet SD, JBJS, 1990
Risk factors
Post operative management
• Bacteremia: oral > GI > GU procedure
• Avoid in first 3-6 mo (high incidence)
AAOS & ADA 1997
• First 2 yrs, specific risk factor for all pts  ATB prophylaxis
• After 2 yrs  consider in high risk pts
Recommended regimens (before procedure 1 hr)
• Cephalexin, cephradine, amoxicillin 2 g. oral
• Cephalosporin 1 g / ampicillin 2 gm IV / IM
• Clindamycin 600 mg oral (allergy to penicillin)
• Clindamycin 600 mg IV / IM (allergy to penicillin)
Advisory statement. J Am Dent Assoc, 1997
Potential risks of hematojenous
total joint infection
• All patients for the first 2 years after joint replacement
• lmmunocompromised / immunosuppressed patients
- Inflammatory arthropathies
- Drug-induced immunosuppression
- Rheumatoid arthritis
- Radiation-induced immunosuppression
- Systemic lupus erythematosus

• Patients with comorbidity conditions
- Previous prosthetic joint infections - HIV infection
- Poor nutrition
- Insulin-dependent diabetes
- Hemophilia
- Malignancy
Advisory statement. J Am Dent Assoc, 1997
Microbiology
Predominant organisms

Goldman RT, CORR, 1996
Microbiology
• Fungal infection = rare
 Candida = predominant

• Mycobacterium tuberculosis = rare
Microbiology

• Mucopolysaccharide biofilm
• Protect from antibodies, phagocytes, ATB.,
• ↑ virulence
Microbiology
• Methicillin-resistant organism  vancomycin
Ries MD, J Arthroplasty, 2001

• Rifampicin = good biofilm & tissue penetration
 improve success when use ĉ other synergistic agent
Zimmerli W, JAMA, 1998
Differential diagnosis
A painful knee is infected until proved otherwise
Insall, 1981

•
•
•
•

Periprosthetic fx
PF problem
Aseptic loosening
Soft tissue disruption

•
•
•
•

Instability
RSD
HO
Arthrofibrosis
Diagnosis
Fundamental of diagnosis
* * * High index of suspicion * * *

Clinical history Physical examination Radiography Aspiration Hematologic
studies

Radionuclide studies

Pathology
Diagnosis
History
• Pain = most common presenting symptom
• Typical = rest / night / persistent / progressive pain
• Progressive stiffness
• Hx of prolong postop drainage, ATB treatment
Physical examination
• Swelling, effusion, warmth, erythema, tenderness
• Painful range of motion
• Persistent wound drainage
 strongly suggestion  early aggressive Rx
Diagnosis
• Swab wound  not recommend
• Empirical ABO for wound drainage  mask symptoms,
affect subsequent C/S, predispose for drug resistant
• Diagnosis in early postop period
– ESR, CRP  limit value
– Typically by arthrocentesis
Aspiration
• Leucocyte count & differentiation
• Gram strain (sens 97%, spec 26%) (
• Culture for aerobic & anarobic bacteria

>1,700/ml3, PMN > 65% (sens 94-97%, spec 88-98%)
Trampuz A, Am J Med, 2004

• Ongoing ATB  stop for several wks before aspiration
Mark Coventry Award Paper
Diagnosis of early post-operative infection following TKA:
The utility of synovial fluid cell count and differential
“Synovial WBC count is an excellent test for diagnosing
infection within 6 wks after 1oTKA
with an optimal cut-off 27,800 cells/mm3 and 89% PMN”
Sens 84%, spec 99%, PPV 94%, NPV 98%
Craig J. Della Valle
Presented at the Knee Society Specialty Day Meeting
March 13, 2010, New Orleans
Hematologic studies
For chronic infection

ESR
– Positive > 30 mm/hr (sens 80%, spec 62.5% )
– False positive: infection elsewhere, inflammation,
CNT dis, neoplasm, recent operation (< 3 mo)
– False negative: prior antibiotics
CRP
– Positive > 10 mg/L (sens & spec 85%)
– Return to normal within 3 wks after operation
ESR + CRP: PPV 83%, NPV 100%
Barrack RL, CORR, 1997
Swanson KC, The adult knee, 2003
Guideline for ESR & CRP
1. Normal ESR & CRP reliable for the absence of infection
2. CRP more useful than ESR for monitoring
3. Use with other tests for the diagnosis of infection

Spangehl MJ, JBJS, 1999
PCR
•
•
•
•
•

Molecular genetic diagnosis
Identify 16S RNA gene
Expensive
Time-dependent
False positive
Remain experimental modality !!!
Mariani BD, CORR, 1996
X-ray
Sequential plain radiographs
• Progressive radiolucencies
• Focal osteopenia / osteolysis of subchondral bone
• Periosteal new bone formation
Morrey BF, CORR, 1989

• Bone destruction – infection present > 10-21 days
• Lytic lesion – destroy 30-50% of bony matrix
Early infection – no abnormal finding !!!
Radioisotope scan
Occasionally helpful in chronic infection
• Tc-99m MDP
• In-111 leukocyte scan
• Tc-99m sulfur colloid
Radioisotope scan
Occasionally helpful in chronic infection
Isotope

Sensitivity Specificity Accuracy

Tc 99m

95%

20%

54%

Indium 111

77%

75%

90%

Tc 99m + In111

100%

97%

97%

Palestro CJ, Radiology, 1991
Intraoperative tissue frozen section
• Widely use
• Result depend on
 Adequate & representative tissue obtaining
 Accurate interpretation by skilled pathologist
> 5 PMN/HPF at least 5 fields  Sens 100%, spec 96%
>10 PMN/HPF at least 5 fields  Sens 25%, spec 98%
Feldman DS, JBJS, 1995
Della Valle CJ, JBJS 1999
Intraoperative tissue frozen section
Reliable predictor for infection

• >10 PMN/HPF: sens 84%, spec 99%, PPV 89%, NPV 98%
• 5-10 PMN/HPF: need other test to differentiate
• <5 PMN/HPF: infection was highly unlikely
Lonner Jh et al, JBJS,1996
Intraoperative gram strain

• Unreliable
• Low sensitivity = 0-14.7%
Atkins BL, J Clin Microbiol, 1998
Della Valle CJ, J Arthroplasty, 1999
Intraoperative culture
Gold standard
Sample: fluid & tissue
 Joint capsule
 Synovial lining
 IM tissue
 Granulation tissue
 Bone fragments
• False +ve: contamination
• False -ve: prior ATB, transport system, lab
- Duff GP, CORR, 1996
- Bauer TW, JBJS, 2006
Definite diagnosis
At least one of the following
1. Same organism from c/s ≥ 2 specimens by aspiration /
deep tissue from surgery
2. Intraarticular tissue histopathology = acute inflammation
3. Gross purulence at the time of surgery
4. Actively discharging sinus tract

Hansen, CORR, 1994
Definite diagnosis
At least one of the following
1. Open wound / sinus tract communicate ĉ joint
2. Systemic signs / symptoms ĉ pain & purulent fluid
3. At least 3 of 5
 ESR > 30 mm/hr
 CRP >10 mg/L
 Frozen section > 5 PMN/HPF
 Preoperative aspiration c/s ≥ 1 +ve
 Intraoperative c/s ≥ 1 +ve
Spangehl MJ, JBJS, 1999
Segawa &Tsukayama classification
“Classify on the basis of clinical presentation”
Type1
Timing

Definition

Type2

Type3

Type4

Positive
intraop C/S

Early
postoperative
infection

Acute
hematogenous
infection

Late (chronic)
infection

Same
Occurring within
organism
first month after
≥2 from C/S
surgery

Hematogenous
Chronic
seeding of
indolent
previously
clinical course;
well-functioning
present >1
prosthesis
month

* * * Guide to treatment * * *
Treatment
Basic treatment options
1.
2.
3.
4.
5.
6.

Antibiotic suppression
Debridement ĉ prosthesis retention
Resection arthroplasty
Arthrodesis
Amputation
Reimplantation - one / two stage
Diagnosis of  infected tka (power point file d r 7)
Diagnosis of  infected tka (power point file d r 7)

More Related Content

What's hot

G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
Success story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccSuccess story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccMohamed Abdulla
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery spa718
 
What's New in Colorectal Cancer Research?
What's New in Colorectal Cancer Research?What's New in Colorectal Cancer Research?
What's New in Colorectal Cancer Research?Fight Colorectal Cancer
 
Adjuvant therapy for Renal Cancer
Adjuvant therapy for Renal CancerAdjuvant therapy for Renal Cancer
Adjuvant therapy for Renal CancerMauricio Lema
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017Mohamed Abdulla
 
La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®Gastrolearning
 
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTSTREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTSspa718
 
M crc ppt
M crc pptM crc ppt
M crc pptmadurai
 
Cetuximab Plus Radiotherapy For Head And Neck Cancer
Cetuximab Plus Radiotherapy For Head And Neck CancerCetuximab Plus Radiotherapy For Head And Neck Cancer
Cetuximab Plus Radiotherapy For Head And Neck Cancerfondas vakalis
 
Estado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásicoEstado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásicoMauricio Lema
 
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MD
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MDMolecular Profiling of Cholangiocarcinoma - Milind Javle, MD
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MDrick435
 
Second line therapy for nsclc
Second line therapy for nsclcSecond line therapy for nsclc
Second line therapy for nsclcfondas vakalis
 
M rcc reempowering an old dogma
M rcc reempowering an old dogmaM rcc reempowering an old dogma
M rcc reempowering an old dogmaMohamed Abdulla
 
20131222 TASL HBV pre-S deletion mutants and HCC outcomes
20131222 TASL HBV pre-S deletion mutants and HCC outcomes 20131222 TASL HBV pre-S deletion mutants and HCC outcomes
20131222 TASL HBV pre-S deletion mutants and HCC outcomes Chien-Wei Su
 
IMRT evidencias clinicas.
IMRT evidencias clinicas.IMRT evidencias clinicas.
IMRT evidencias clinicas.Ignacio Sisamon
 

What's hot (20)

G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
Success story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccSuccess story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rcc
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery
 
What's New in Colorectal Cancer Research?
What's New in Colorectal Cancer Research?What's New in Colorectal Cancer Research?
What's New in Colorectal Cancer Research?
 
Adjuvant therapy for Renal Cancer
Adjuvant therapy for Renal CancerAdjuvant therapy for Renal Cancer
Adjuvant therapy for Renal Cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
Asi kovalam
Asi  kovalamAsi  kovalam
Asi kovalam
 
Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017
 
La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®
 
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTSTREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
TREATMENT OF NON-HIDGKIN'S LYMPHOMA IN ELDERLY PATIENTS
 
IO en NSCLC
IO en NSCLCIO en NSCLC
IO en NSCLC
 
M crc ppt
M crc pptM crc ppt
M crc ppt
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
Cetuximab Plus Radiotherapy For Head And Neck Cancer
Cetuximab Plus Radiotherapy For Head And Neck CancerCetuximab Plus Radiotherapy For Head And Neck Cancer
Cetuximab Plus Radiotherapy For Head And Neck Cancer
 
Estado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásicoEstado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásico
 
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MD
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MDMolecular Profiling of Cholangiocarcinoma - Milind Javle, MD
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MD
 
Second line therapy for nsclc
Second line therapy for nsclcSecond line therapy for nsclc
Second line therapy for nsclc
 
M rcc reempowering an old dogma
M rcc reempowering an old dogmaM rcc reempowering an old dogma
M rcc reempowering an old dogma
 
20131222 TASL HBV pre-S deletion mutants and HCC outcomes
20131222 TASL HBV pre-S deletion mutants and HCC outcomes 20131222 TASL HBV pre-S deletion mutants and HCC outcomes
20131222 TASL HBV pre-S deletion mutants and HCC outcomes
 
IMRT evidencias clinicas.
IMRT evidencias clinicas.IMRT evidencias clinicas.
IMRT evidencias clinicas.
 

Viewers also liked

Polish Stocks 2. December 2016
Polish Stocks 2. December 2016 Polish Stocks 2. December 2016
Polish Stocks 2. December 2016 Gieldowy Wizjer
 
Las estaciones del año
Las estaciones del añoLas estaciones del año
Las estaciones del añoNatyVidal46
 
Magazine world is magnifique june 2014
Magazine world is magnifique june 2014Magazine world is magnifique june 2014
Magazine world is magnifique june 2014Prakash Montroy
 
How to become a freelancer AND training for freelancers
How to become a freelancer AND training for freelancersHow to become a freelancer AND training for freelancers
How to become a freelancer AND training for freelancerscarahulray
 
Polish Stocks 6. January 2017
Polish Stocks 6. January 2017 Polish Stocks 6. January 2017
Polish Stocks 6. January 2017 Gieldowy Wizjer
 
Η Διδασκαλία του Ιησού
Η Διδασκαλία του ΙησούΗ Διδασκαλία του Ιησού
Η Διδασκαλία του Ιησούangelosozil118
 
Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24
Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24
Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24Lana Pedneault
 
Biblia szkoleń giełdowych
Biblia szkoleń giełdowychBiblia szkoleń giełdowych
Biblia szkoleń giełdowychGieldowy Wizjer
 
Campbell glo call 2013
Campbell glo call 2013Campbell glo call 2013
Campbell glo call 2013David Campbell
 
CDP Supply-Chain-report-2015
CDP Supply-Chain-report-2015CDP Supply-Chain-report-2015
CDP Supply-Chain-report-2015Siddhant Mishra
 
World is magnifique sept oct 2014
World is magnifique sept oct 2014World is magnifique sept oct 2014
World is magnifique sept oct 2014Prakash Montroy
 

Viewers also liked (17)

Polish Stocks 2. December 2016
Polish Stocks 2. December 2016 Polish Stocks 2. December 2016
Polish Stocks 2. December 2016
 
herbal untuk Hipertensi
herbal untuk Hipertensiherbal untuk Hipertensi
herbal untuk Hipertensi
 
Prsa 2
Prsa 2Prsa 2
Prsa 2
 
Super cars
Super carsSuper cars
Super cars
 
Las estaciones del año
Las estaciones del añoLas estaciones del año
Las estaciones del año
 
Magazine world is magnifique june 2014
Magazine world is magnifique june 2014Magazine world is magnifique june 2014
Magazine world is magnifique june 2014
 
Links
LinksLinks
Links
 
Buying A Land ?
Buying A Land ?Buying A Land ?
Buying A Land ?
 
Delhi Metro
Delhi MetroDelhi Metro
Delhi Metro
 
How to become a freelancer AND training for freelancers
How to become a freelancer AND training for freelancersHow to become a freelancer AND training for freelancers
How to become a freelancer AND training for freelancers
 
Polish Stocks 6. January 2017
Polish Stocks 6. January 2017 Polish Stocks 6. January 2017
Polish Stocks 6. January 2017
 
Η Διδασκαλία του Ιησού
Η Διδασκαλία του ΙησούΗ Διδασκαλία του Ιησού
Η Διδασκαλία του Ιησού
 
Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24
Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24
Présentation Comité de Citoyens Vaudreuil Durable 2016 11-24
 
Biblia szkoleń giełdowych
Biblia szkoleń giełdowychBiblia szkoleń giełdowych
Biblia szkoleń giełdowych
 
Campbell glo call 2013
Campbell glo call 2013Campbell glo call 2013
Campbell glo call 2013
 
CDP Supply-Chain-report-2015
CDP Supply-Chain-report-2015CDP Supply-Chain-report-2015
CDP Supply-Chain-report-2015
 
World is magnifique sept oct 2014
World is magnifique sept oct 2014World is magnifique sept oct 2014
World is magnifique sept oct 2014
 

Similar to Diagnosis of infected tka (power point file d r 7)

Management of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcomaManagement of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcomaPRARABDH95
 
Externalbeam rt in ews3.12.20 - frida yseminar-finallll
Externalbeam rt in ews3.12.20    - frida yseminar-finallllExternalbeam rt in ews3.12.20    - frida yseminar-finallll
Externalbeam rt in ews3.12.20 - frida yseminar-finallllPRARABDH95
 
Evidence Based Approach to PTE
Evidence Based Approach to PTEEvidence Based Approach to PTE
Evidence Based Approach to PTEKristopher Maday
 
Evidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismEvidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismKristopher Maday
 
Giant Cell Tumors of Bones: Management & Single Author Experience
Giant Cell Tumors of Bones: Management & Single Author ExperienceGiant Cell Tumors of Bones: Management & Single Author Experience
Giant Cell Tumors of Bones: Management & Single Author ExperienceMohamed Abdulla
 
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRFebrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRDR Saqib Shah
 
Surgical treatment of spinal TB
Surgical treatment of spinal TBSurgical treatment of spinal TB
Surgical treatment of spinal TBManishShrestha51
 
Microbiological Investigation of Osteo-articular infections
Microbiological Investigation of Osteo-articular infectionsMicrobiological Investigation of Osteo-articular infections
Microbiological Investigation of Osteo-articular infectionsMahen Kothalawala
 
Nasopharyngeal cancer
Nasopharyngeal cancer Nasopharyngeal cancer
Nasopharyngeal cancer Ajay Manickam
 
Acute osteomyelitis
Acute osteomyelitisAcute osteomyelitis
Acute osteomyelitisbijay19
 
Approach to a patient with respiratory infection
Approach to a patient with respiratory infectionApproach to a patient with respiratory infection
Approach to a patient with respiratory infectionSrikant Mohta
 
Advancement in treatment of ra (1)
Advancement in treatment of ra (1)Advancement in treatment of ra (1)
Advancement in treatment of ra (1)Naveen Kumar
 
Osteomyelitis and Septic arthritis.pptx
Osteomyelitis and Septic arthritis.pptxOsteomyelitis and Septic arthritis.pptx
Osteomyelitis and Septic arthritis.pptxAlexHaile2
 
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdfMANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdfadhilaamariyil
 
16. suman mallik 999999999999999(2).pptx
16. suman mallik 999999999999999(2).pptx16. suman mallik 999999999999999(2).pptx
16. suman mallik 999999999999999(2).pptxBramhendraNaik1
 
Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)BBrauer25
 
Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014BBrauer25
 

Similar to Diagnosis of infected tka (power point file d r 7) (20)

Management of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcomaManagement of ewings sarcoma & osteosarcoma
Management of ewings sarcoma & osteosarcoma
 
Externalbeam rt in ews3.12.20 - frida yseminar-finallll
Externalbeam rt in ews3.12.20    - frida yseminar-finallllExternalbeam rt in ews3.12.20    - frida yseminar-finallll
Externalbeam rt in ews3.12.20 - frida yseminar-finallll
 
Evidence Based Approach to PTE
Evidence Based Approach to PTEEvidence Based Approach to PTE
Evidence Based Approach to PTE
 
Evidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismEvidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary Thromboembolism
 
TB SPINE.pptx
TB SPINE.pptxTB SPINE.pptx
TB SPINE.pptx
 
Giant Cell Tumors of Bones: Management & Single Author Experience
Giant Cell Tumors of Bones: Management & Single Author ExperienceGiant Cell Tumors of Bones: Management & Single Author Experience
Giant Cell Tumors of Bones: Management & Single Author Experience
 
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRFebrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
 
Surgical treatment of spinal TB
Surgical treatment of spinal TBSurgical treatment of spinal TB
Surgical treatment of spinal TB
 
Microbiological Investigation of Osteo-articular infections
Microbiological Investigation of Osteo-articular infectionsMicrobiological Investigation of Osteo-articular infections
Microbiological Investigation of Osteo-articular infections
 
Fever of unknown origin
Fever of unknown originFever of unknown origin
Fever of unknown origin
 
Nasopharyngeal cancer
Nasopharyngeal cancer Nasopharyngeal cancer
Nasopharyngeal cancer
 
Acute osteomyelitis
Acute osteomyelitisAcute osteomyelitis
Acute osteomyelitis
 
Acute osteomyelitis
Acute osteomyelitisAcute osteomyelitis
Acute osteomyelitis
 
Approach to a patient with respiratory infection
Approach to a patient with respiratory infectionApproach to a patient with respiratory infection
Approach to a patient with respiratory infection
 
Advancement in treatment of ra (1)
Advancement in treatment of ra (1)Advancement in treatment of ra (1)
Advancement in treatment of ra (1)
 
Osteomyelitis and Septic arthritis.pptx
Osteomyelitis and Septic arthritis.pptxOsteomyelitis and Septic arthritis.pptx
Osteomyelitis and Septic arthritis.pptx
 
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdfMANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
MANAGEMENT 0F SEMINOMA CURRENT STATUS AND FUTURE DIRECTIONS.pdf
 
16. suman mallik 999999999999999(2).pptx
16. suman mallik 999999999999999(2).pptx16. suman mallik 999999999999999(2).pptx
16. suman mallik 999999999999999(2).pptx
 
Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)
 
Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014
 

Diagnosis of infected tka (power point file d r 7)

  • 1. Diagnosis of Infected total knee arthroplasty Warakorn Jingjit, MD Orthopaedic Department, Faculty of Medicine Chiang Mai University
  • 2. One of the most devastating & challenging complication Immense financial & psychological burden Cost of treatment 15,000 - 60,000 $ / TKA Hebert CK, CORR, 1996 Sculco TP, Orthopedics, 1995
  • 3. Incidence • 0.39% in primary TKA • 0.97% in revision TKA
  • 4. Projection of the TKA & THA number Kurtz S, JBJS, 2008
  • 5. Projection of the TKA & THA infection Kurtz S, JBJS, 2007
  • 6. Risk factors 1. 2. 3. 4. Patient / host Surgical environment Surgical technique Postoperative management
  • 7. Risk factors Patient / host • Immunocompromise • – RA (4.4%) – Steroid therapy – DM (7%) – Poor nutrition • Albumin <3.5g/dl: 7-fold • Lymphocyte <1,500 cells/mm3: 5-fold • – HIV – Organ transplant • • • • Hypokalemia Tobacco use Obesity • • • Debilitation – – – – – Advanced age Alcoholism Renal failure Cirrhosis Prolonged pre-op hospitalization Hypothyroidism Previous surgery Psoriasis Previous infection Concurrent infection
  • 8. Risk factors Surgical environment • Personnel • Clean air Laminar air flow, UV light • Surgical attire • Operative site preparation Ritter MA, CORR,1988 Ritter MA, Orthop Clin North Am,1989 Berg M, JBJS (Br), 1991 Ritter MA, CORR, 1999 Peersman G, CORR, 2001
  • 9. Risk factors Surgical technique • Surgical time Operative time > 2.5 hrs Peersman, CORR, 2001
  • 10. Risk factors Surgical technique Prophylactic antibiotic Single most effective method of ↓ infection 1st gen. cephalosporin Allergy  vancomycin / clindamycin 30-60 min before incision (peak serum bone conc. within 20 min)  Repeat every 4 hrs & bleed >1,000 ml  Discontinue 24 hrs after surgery    
  • 11. Risk factors Surgical technique Prophylactic antibiotic bone cement • High risk 1o TKA, revision TKA
  • 12. Risk factors Surgical technique Implant • Hinged prosthesis • Infection rate at 10 yrs ~ 15% • Bengtson S, Acta Orthop Scand, 1991 • Hanssen AD, CORR, 1995 • Schoifet SD, JBJS, 1990
  • 13. Risk factors Post operative management • Bacteremia: oral > GI > GU procedure • Avoid in first 3-6 mo (high incidence) AAOS & ADA 1997 • First 2 yrs, specific risk factor for all pts  ATB prophylaxis • After 2 yrs  consider in high risk pts Recommended regimens (before procedure 1 hr) • Cephalexin, cephradine, amoxicillin 2 g. oral • Cephalosporin 1 g / ampicillin 2 gm IV / IM • Clindamycin 600 mg oral (allergy to penicillin) • Clindamycin 600 mg IV / IM (allergy to penicillin) Advisory statement. J Am Dent Assoc, 1997
  • 14. Potential risks of hematojenous total joint infection • All patients for the first 2 years after joint replacement • lmmunocompromised / immunosuppressed patients - Inflammatory arthropathies - Drug-induced immunosuppression - Rheumatoid arthritis - Radiation-induced immunosuppression - Systemic lupus erythematosus • Patients with comorbidity conditions - Previous prosthetic joint infections - HIV infection - Poor nutrition - Insulin-dependent diabetes - Hemophilia - Malignancy Advisory statement. J Am Dent Assoc, 1997
  • 16. Microbiology • Fungal infection = rare  Candida = predominant • Mycobacterium tuberculosis = rare
  • 17. Microbiology • Mucopolysaccharide biofilm • Protect from antibodies, phagocytes, ATB., • ↑ virulence
  • 18. Microbiology • Methicillin-resistant organism  vancomycin Ries MD, J Arthroplasty, 2001 • Rifampicin = good biofilm & tissue penetration  improve success when use ĉ other synergistic agent Zimmerli W, JAMA, 1998
  • 19. Differential diagnosis A painful knee is infected until proved otherwise Insall, 1981 • • • • Periprosthetic fx PF problem Aseptic loosening Soft tissue disruption • • • • Instability RSD HO Arthrofibrosis
  • 20. Diagnosis Fundamental of diagnosis * * * High index of suspicion * * * Clinical history Physical examination Radiography Aspiration Hematologic studies Radionuclide studies Pathology
  • 21. Diagnosis History • Pain = most common presenting symptom • Typical = rest / night / persistent / progressive pain • Progressive stiffness • Hx of prolong postop drainage, ATB treatment Physical examination • Swelling, effusion, warmth, erythema, tenderness • Painful range of motion • Persistent wound drainage  strongly suggestion  early aggressive Rx
  • 22. Diagnosis • Swab wound  not recommend • Empirical ABO for wound drainage  mask symptoms, affect subsequent C/S, predispose for drug resistant • Diagnosis in early postop period – ESR, CRP  limit value – Typically by arthrocentesis
  • 23. Aspiration • Leucocyte count & differentiation • Gram strain (sens 97%, spec 26%) ( • Culture for aerobic & anarobic bacteria >1,700/ml3, PMN > 65% (sens 94-97%, spec 88-98%) Trampuz A, Am J Med, 2004 • Ongoing ATB  stop for several wks before aspiration
  • 24. Mark Coventry Award Paper Diagnosis of early post-operative infection following TKA: The utility of synovial fluid cell count and differential “Synovial WBC count is an excellent test for diagnosing infection within 6 wks after 1oTKA with an optimal cut-off 27,800 cells/mm3 and 89% PMN” Sens 84%, spec 99%, PPV 94%, NPV 98% Craig J. Della Valle Presented at the Knee Society Specialty Day Meeting March 13, 2010, New Orleans
  • 25. Hematologic studies For chronic infection ESR – Positive > 30 mm/hr (sens 80%, spec 62.5% ) – False positive: infection elsewhere, inflammation, CNT dis, neoplasm, recent operation (< 3 mo) – False negative: prior antibiotics CRP – Positive > 10 mg/L (sens & spec 85%) – Return to normal within 3 wks after operation ESR + CRP: PPV 83%, NPV 100% Barrack RL, CORR, 1997 Swanson KC, The adult knee, 2003
  • 26. Guideline for ESR & CRP 1. Normal ESR & CRP reliable for the absence of infection 2. CRP more useful than ESR for monitoring 3. Use with other tests for the diagnosis of infection Spangehl MJ, JBJS, 1999
  • 27. PCR • • • • • Molecular genetic diagnosis Identify 16S RNA gene Expensive Time-dependent False positive Remain experimental modality !!! Mariani BD, CORR, 1996
  • 28. X-ray Sequential plain radiographs • Progressive radiolucencies • Focal osteopenia / osteolysis of subchondral bone • Periosteal new bone formation Morrey BF, CORR, 1989 • Bone destruction – infection present > 10-21 days • Lytic lesion – destroy 30-50% of bony matrix Early infection – no abnormal finding !!!
  • 29. Radioisotope scan Occasionally helpful in chronic infection • Tc-99m MDP • In-111 leukocyte scan • Tc-99m sulfur colloid
  • 30. Radioisotope scan Occasionally helpful in chronic infection Isotope Sensitivity Specificity Accuracy Tc 99m 95% 20% 54% Indium 111 77% 75% 90% Tc 99m + In111 100% 97% 97% Palestro CJ, Radiology, 1991
  • 31. Intraoperative tissue frozen section • Widely use • Result depend on  Adequate & representative tissue obtaining  Accurate interpretation by skilled pathologist > 5 PMN/HPF at least 5 fields  Sens 100%, spec 96% >10 PMN/HPF at least 5 fields  Sens 25%, spec 98% Feldman DS, JBJS, 1995 Della Valle CJ, JBJS 1999
  • 32. Intraoperative tissue frozen section Reliable predictor for infection • >10 PMN/HPF: sens 84%, spec 99%, PPV 89%, NPV 98% • 5-10 PMN/HPF: need other test to differentiate • <5 PMN/HPF: infection was highly unlikely Lonner Jh et al, JBJS,1996
  • 33. Intraoperative gram strain • Unreliable • Low sensitivity = 0-14.7% Atkins BL, J Clin Microbiol, 1998 Della Valle CJ, J Arthroplasty, 1999
  • 34. Intraoperative culture Gold standard Sample: fluid & tissue  Joint capsule  Synovial lining  IM tissue  Granulation tissue  Bone fragments • False +ve: contamination • False -ve: prior ATB, transport system, lab - Duff GP, CORR, 1996 - Bauer TW, JBJS, 2006
  • 35. Definite diagnosis At least one of the following 1. Same organism from c/s ≥ 2 specimens by aspiration / deep tissue from surgery 2. Intraarticular tissue histopathology = acute inflammation 3. Gross purulence at the time of surgery 4. Actively discharging sinus tract Hansen, CORR, 1994
  • 36. Definite diagnosis At least one of the following 1. Open wound / sinus tract communicate ĉ joint 2. Systemic signs / symptoms ĉ pain & purulent fluid 3. At least 3 of 5  ESR > 30 mm/hr  CRP >10 mg/L  Frozen section > 5 PMN/HPF  Preoperative aspiration c/s ≥ 1 +ve  Intraoperative c/s ≥ 1 +ve Spangehl MJ, JBJS, 1999
  • 37.
  • 38. Segawa &Tsukayama classification “Classify on the basis of clinical presentation” Type1 Timing Definition Type2 Type3 Type4 Positive intraop C/S Early postoperative infection Acute hematogenous infection Late (chronic) infection Same Occurring within organism first month after ≥2 from C/S surgery Hematogenous Chronic seeding of indolent previously clinical course; well-functioning present >1 prosthesis month * * * Guide to treatment * * *
  • 39. Treatment Basic treatment options 1. 2. 3. 4. 5. 6. Antibiotic suppression Debridement ĉ prosthesis retention Resection arthroplasty Arthrodesis Amputation Reimplantation - one / two stage